877459-36-4
877459-36-4
Chemical Structure
TGN-073
- CAS No.: 877459-36-4
- Formula:C18H16N2O3S
- Molecular Weight:340.40
IUPAC Name: N-(3-(benzyloxy)pyridin-2-yl)benzenesulfonamide
InChIKey: JBHHMMLJGNLVNB-UHFFFAOYSA-N
SMILES: O=S(C1=CC=CC=C1)(NC2=NC=CC=C2OCC3=CC=CC=C3)=O
Biological Activity: TGN-073 is an orally active, blood-brain barrier-permeable aquaporin 4 (AQP4) modulator. TGN-073 increases the uptake and distribution of brain MRI tracers in the brain parenchyma and reduces the levels of insoluble amyloid β-40 and β-42. TGN-073 can be used in research related to Alzheimer's disease, dementia, traumatic brain injury and pain[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
TGN-073 | 99.53% | TGN-073 is an orally active, blood-brain barrier-permeable aquaporin 4 (AQP4) modulator. TGN-073 increases the uptake and distribution of brain MRI tracers in the brain parenchyma and reduces the levels of insoluble amyloid β-40 and β-42. TGN-073 can be used in research related to Alzheimer's disease, dementia, traumatic brain injury and pain. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DapL-IN-1 | DapL-IN-1 is an inhibitor of L,L-diaminoheptanoic acid aminotransferase (DapL) with the characteristics of inhibiting DapL activity in bacteria and plants. DapL-IN-1 can be used to design and discover new biocides such as antibiotics, herbicides or algaecides with the potential to be non-toxic to animals. DapL-IN-1 shows differential sensitivity in inhibiting different DapL homologues, which can provide important information for further drug development. DapL-IN-1 may affect its biological activity by affecting the interaction with residues adjacent to the active site, which may lead to different binding modes. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Benzyl 2-naphthyl ether | 99.44% | Benzyl 2-naphthyl ether is a compound mentioned in the study of the effects of aromatic sensitizers on zebrafish embryos. It can cause morphological abnormalities and changes in gene expression in zebrafish embryos. Its toxicity mechanism is partly related to AHR, and there may be other mechanisms independent of AHR. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
OU749 | 99.07% | OU749 is a potent γ-glutamyl transpeptidase (GGT) inhibitor with a Ki value of 17.6 µM. OU749 shows cytotoxicity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Carbonic anhydrase inhibitor 22 | Carbonic anhydrase inhibitor 22 (Compd 2g), a sulfonamide carbonic anhydrase inhibitor, with Ki values of 762 nM (hCA I), 20.3 nM (hCA II), 8.3 nM (hCA VII), 17.9 nM (hCA IX) and 10.5 nM (hCA XII), repectively. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
AR antagonist 3 | 99.96% | AR antagonist 3 is a potent and selective androgen receptor (AR) antagonist with an IC50 of 0.47 µM. AR antagonist 3 exhibits a dose-dependent decrease of the FRET signal (IC50= 18.05 μM). AR antagonist 3 shows effective inhibition on tumor growth when administered intratumorally. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
β-catenin-IN-7 | β-catenin-IN-7 (Compound 9) is a β-catenin inhibitor. β-catenin-IN-7 inhibits the interaction between β-catenin and Tcf-4, and inhibits Wnt-dependent target gene expression. β-catenin-IN-7 has anti-cancer activity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ChEs/MAOs-IN-2 | ChEs/MAOs-IN-2 (compound a11) is a cholinesterases and monoamine oxidases inhibitor with IC50 values of 0.10, 0.20, 0.30, 0.40 µM for MAO-A, MAO-B, AChE, and BChE, respectively. ChEs/MAOs-IN-2 has the potential for the research of Alzheimer's disease. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
dRRM-1 | dRRM-1 is a DCAF15-dependent RBM39/RBM23 molecular glue degrader. dRRM-1 stabilizes the interaction between DCAF15 and the novel substrates RBM39 and RBM23, thereby triggering their ubiquitination and degradation. dRRM-1 can be applied in research related to cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Sulfapyridine | 99.85% | Sulfapyridine, a major metabolite of Sulfasalazine, is a sulfonamide antibiotic agent. Sulfapyridine inhibits recombinant P. carinii dihydropteroate synthetase (DHPS) with an IC50 of 0.18 μM. Sulfapyridine has antibacterial, anti-inflammatory and anti-rheumatic activities. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Sulfaquinoxaline | 99.46% | Sulfaquinoxaline is an antimicrobial for veterinary use, with activity against a broad spectrum of Gram-negative and Gram-positive bacteria. Sulfaquinoxaline is used to prevent coccidiosis and bacterial infections. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Alghanimy A, et al. The effect of a novel AQP4 facilitator, TGN-073, on glymphatic transport captured by diffusion MRI and DCE-MRI. PLoS One. 2023;18(3):e0282955. Published 2023 Mar 15. [Content Brief]
- [2]. Ingrid L. Kwee, et al. Aquaporin4 facilitator decreases insoluble amyloid b of 5XFAD mouse brain. Alzheimer's Association. 07 December 2020.
- [3]. Vincent J. et al. Aquaporin-4 facilitator TGN-073 demonstrates novel analgesic activity. bioRxiv. October 08, 2018.
